FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis

Table 6 The evaluation of seven non-invasive models for diagnosing high-risk metabolic dysfunction associated steatohepatitis

Non-invasive models	High threshold criteria	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUROC (95%CI)	P value
Overall population
FIB-4	2.67	26.9	95.2	73.5	72.2	0.75 (0.69-0.81)	< 0.05
APRI	1.50	24.7	93.0	63.9	71.2	0.69 (0.63-0.76)	< 0.05
Forns index	6.90	18.3	94.6	63.0	69.8	0.67 (0.61-0.74)	< 0.05
ARR	1.00	21.5	92.5	58.8	70.2	0.68 (0.61-0.74)	< 0.05
S index	0.50	11.8	91.9	42.3	67.6	0.62 (0.55-0.69)	< 0.05
GPR	0.56	69.9	44.6	38.7	74.8	0.60 (0.53-0.67)	< 0.05
Subgroup population
FAST	0.67	44.2	92.3	82.1	67.4	0.82 (0.74-0.90)	< 0.05
FIB-4	2.67	25.0	96.9	86.7	61.8	0.76 (0.68-0.85)	< 0.05
APRI	1.50	19.2	96.9	83.3	60.0	0.74 (0.65-0.83)	< 0.05
Forns index	6.90	17.3	95.4	75.0	59.0	0.68 (0.58-0.77)	< 0.05
ARR	1.00	23.1	87.7	60.0	58.8	0.62 (0.52-0.72)	< 0.05
S index	0.50	7.7	95.4	57.1	56.4	0.54 (0.43-0.64)	0.50
GPR	0.56	63.5	32.3	42.9	52.5	0.51 (0.41-0.62)	0.80

PPV: Positive predictive value; NPV: Negative predictive value; AUROC: The area under the receiver operating characteristic curves; FAST: FibroScan-aspartate transaminase; FIB-4: Fibrosis-4; APRI: Aspartate transaminase to platelet ratio index; ARR: Aspartate transaminase to alanine transaminase ratio; GPR: Gamma-glutamyl transpeptidase to platelet ratio.